The Lynx Group
Cholangiocarcinoma News

Cholangiocarcinoma

This edition of Year in Review is focused on cholangiocarcinoma (CCA), which is a diverse group of malignancies characterized by genomic heterogeneity that potentially drives its pathogenesis. Below is a quick review of some of the topics discussed in this issue, with a focus on recent advances, potentially practice-changing developments, and ongoing challenges in CCA.
Read More

Real-world evidence demonstrates a survival advantage for patients with CCA harboring FGFR2 fusions/rearrangements compared with those with FGFR2 wild-type CCA.
Read More

Mature results from a phase 2 study demonstrated that the FGFR inhibitor infigratinib has antitumor activity and a manageable adverse event profile in previously treated patients with locally advanced or metastatic CCA harboring FGFR2 gene fusions or rearrangements.
Read More

Final results of the ClarIDHy trial demonstrated the clinical benefit of ivosidenib in patients with previously treated unresectable or metastatic CCA harboring an IDH1 mutation.
Read More

Updated results from the FIGHT-202 study supported the primary data that second-line pemigatinib treatment resulted in efficacy and sustained tolerability in patients with CCA harboring FGFR2 rearrangements/fusions.
Read More

Findings from a study in a Chinese patient population confirmed the efficacy and tolerability of pemigatinib in patients with recurrent or metastatic CCA with an FGFR2 fusion or rearrangement.
Read More

Longitudinal evaluation of quality of life in pemigatinib-treated patients with advanced CCA harboring FGFR fusions/rearrangements showed that those who achieved complete response/partial response or stable disease exhibited stable overall health status and emotional functioning.
Read More

Initial results of the phase 2 FOENIX-CCA2 study demonstrated that second-line futibatinib was active and had a manageable safety profile in patients with intrahepatic CCA harboring FGFR2 fusion/rearrangements.
Read More

Findings of patient-reported outcomes from the phase 2 FOENIX-CCA2 study indicate that quality-of-life data and overall health status were maintained among futibatinib-treated patients with advanced intrahepatic CCA.
Read More

Results of this retrospective pooled safety analysis indicate that futibatinib was safe and tolerable in patients with advanced solid tumors, including intrahepatic CCA.
Read More

Page 1 of 8

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: